

# Marco Ripa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5448979/publications.pdf>

Version: 2024-02-01

37  
papers

1,978  
citations

516215

16  
h-index

377514

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

4785  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	2.2	808
2	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	1.0	349
3	Eosinophils from Physiology to Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2018, 2018, 1-28.	0.9	182
4	Role of Rehabilitation Department for Adult Individuals With COVID-19: The Experience of the San Raffaele Hospital of Milan. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020, 101, 1656-1661.	0.5	58
5	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49
6	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	1.1	49
7	LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 11-18.	1.4	46
8	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 3631-3641.	0.6	46
9	Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 136-139.	0.9	43
10	Bowel perforation in a Covid-19 patient: case report. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1797-1800.	1.0	40
11	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , 2022, 64, .	0.2	36
12	One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1354-1363.	0.6	33
13	Ceftobiprole for the treatment of infective endocarditis: A case series. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 56-59.	0.9	27
14	Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	23
15	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3443-3452.	1.3	20
16	Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2019, 184, 181-185.	1.3	17
17	The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 1974.	1.0	16
18	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. <i>Journal of Medical Virology</i> , 2019, 91, 1937-1943.	2.5	13
20	Outcomes of noninvasive ventilation as the ceiling of treatment in patients with COVID-19. <i>Panminerva Medica</i> , 2022, 64, .	0.2	13
21	Myocardial injury in patients with SARS-CoV-2 pneumonia: Pivotal role of inflammation in COVID-19. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13703.	1.7	13
22	Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets. <i>PLoS ONE</i> , 2015, 10, e0140435.	1.1	11
23	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1391-1395.	1.3	10
24	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 492-499.	1.1	10
25	Immunosenescence and hurdles in the clinical management of older HIV-patients. <i>Virulence</i> , 2017, 8, 508-528.	1.8	9
26	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 632-633.	1.3	9
27	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016, 95, e3780.	0.4	6
28	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1732-1733.	1.3	6
29	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1436-1439.	1.3	5
30	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017, 17, 723.	1.3	5
31	Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient. <i>International Journal of STD and AIDS</i> , 2013, 24, 980-982.	0.5	3
32	Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e27-e29.	0.9	3
33	Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up. <i>Journal of Clinical Virology</i> , 2016, 85, 86-89.	1.6	2
34	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1549-1550.	1.3	1
35	Clinical characteristics and outcome of infective endocarditis due to Abiotrophia and Granulicatella compared to Viridans group streptococci. <i>Journal of Infection</i> , 2022, 85, 137-146.	1.7	1
36	HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications. <i>ISRN Virology</i> , 2014, 2014, 1-6.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Postâ€transplant cyclophosphamide to overcome the HLAâ€matching barrier. <i>Transplant Infectious Disease</i> , 2021, 23, e13551.	0.7	0